CDKN2A and neoplasm: Targeted sequencing often observes mutations in the CDKN2A gene (chromosome 9p) in LGSOCs; its gene product, the tumor suppressor p16, normally inhibits the G1 phase of the cell cycle via cyclin-dependent kinases (CDK) 4 and 6, which play a crucial role cell cycle progression and are responsible for phosphorylation of the retinobloblastoma (Rb) protein, inactivating its tumor suppressor function [87].